{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:30:32Z","timestamp":1787675432941,"version":"build-2784847793"},"reference-count":63,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Biogen (US)","award":["SPO#146627"],"award-info":[{"award-number":["SPO#146627"]}]},{"name":"Biogen (US)","award":["SPO #268261"],"award-info":[{"award-number":["SPO #268261"]}]},{"name":"Biogen (US)","award":["Cure SMA: #116507"],"award-info":[{"award-number":["Cure SMA: #116507"]}]},{"name":"SMA Foundation","award":["SPO#146627"],"award-info":[{"award-number":["SPO#146627"]}]},{"name":"SMA Foundation","award":["SPO #268261"],"award-info":[{"award-number":["SPO #268261"]}]},{"name":"SMA Foundation","award":["Cure SMA: #116507"],"award-info":[{"award-number":["Cure SMA: #116507"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Disease-modifying treatments have transformed the natural history of spinal muscular atrophy (SMA), but the cellular pathways altered by SMN restoration remain undefined and biomarkers cannot yet precisely predict treatment response. We performed an exploratory cerebrospinal fluid (CSF) proteomic study in a diverse sample of SMA patients treated with nusinersen to elucidate therapeutic pathways and identify predictors of motor improvement. Proteomic analyses were performed on CSF samples collected before treatment (T0) and at 6 months (T6) using an Olink panel to quantify 1113 peptides. A supervised machine learning approach was used to identify proteins that discriminated patients who improved functionally from those who did not after 2 years of treatment. A total of 49 SMA patients were included (10 type 1, 18 type 2, and 21 type 3), ranging in age from 3 months to 65 years. Most proteins showed a decrease in CSF concentration at T6. The machine learning algorithm identified ARSB, ENTPD2, NEFL, and IFI30 as the proteins most predictive of improvement. The machine learning model was able to predict motor improvement at 2 years with 79.6% accuracy. The results highlight the potential application of CSF biomarkers to predict motor improvement following SMA treatment. Validation in larger datasets is needed.<\/jats:p>","DOI":"10.3390\/jcm12206696","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T10:32:24Z","timestamp":1698057144000},"page":"6696","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8615-4390","authenticated-orcid":false,"given":"Marie","family":"Beaudin","sequence":"first","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"},{"name":"Department of Neurology, Stanford Health Care, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Kamali","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1790-8221","authenticated-orcid":false,"given":"Katharine A.","family":"Hagerman","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9322-0608","authenticated-orcid":false,"given":"Sally","family":"Dunaway Young","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"},{"name":"Department of Neurology, Stanford Health Care, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ghiglieri","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-412X","authenticated-orcid":false,"given":"Dana M.","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Lehallier","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Tesi-Rocha","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"},{"name":"Department of Neurology, Stanford Health Care, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinda B.","family":"Sampson","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"},{"name":"Department of Neurology, Stanford Health Care, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Duong","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"},{"name":"Department of Neurology, Stanford Health Care, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Day","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA"},{"name":"Department of Neurology, Stanford Health Care, Stanford, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Niri, F., Nicholls, J., Baptista Wyatt, K., Walker, C., Price, T., Kelln, R., Hume, S., Parboosingh, J., Lilley, M., and Kolski, H. (2023). Alberta Spinal Muscular Atrophy Newborn Screening-Results from Year 1 Pilot Project. Int. J. Neonatal Screen., 9.","DOI":"10.3390\/ijns9030042"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/JND-221577","article-title":"Newbornscreening SMA\u2014From Pilot Project to Nationwide Screening in Germany","volume":"10","author":"Blaschek","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jmg-2022-108873","article-title":"Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: Towards specific guidelines and standard operating procedures for the molecular diagnosis","volume":"60","author":"Abiusi","year":"2023","journal-title":"J. Med. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1527","DOI":"10.1212\/WNL.0000000000200986","article-title":"Newborn Screening for Spinal Muscular Atrophy in New York State: Clinical Outcomes From the First 3 Years","volume":"99","author":"Lee","year":"2022","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/hmg\/ddab350","article-title":"Antisense oligonucleotides targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy cell lines and mouse model","volume":"31","author":"Wang","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ahg.12031","article-title":"Spinal muscular atrophy: From gene discovery to clinical trials","volume":"77","author":"Nurputra","year":"2013","journal-title":"Ann. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"Mailman","year":"2002","journal-title":"Genet. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: A critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3","volume":"91","author":"Maggi","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/ene.15501","article-title":"Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts\u2019 study","volume":"29","author":"Povedano","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","article-title":"Nusinersen Treatment in Adults with Spinal Muscular Atrophy","volume":"11","author":"Duong","year":"2021","journal-title":"Neurol. Clin. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"Bertini","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(20)30183-6","article-title":"Natural history data in adults with SMA","volume":"19","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Babic, M., Banovic, M., Berecic, I., Banic, T., Babic Leko, M., Ulamec, M., Junakovic, A., Kopic, J., Sertic, J., and Barisic, N. (2023). Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular Atrophy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12155060"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/acn3.51449","article-title":"Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children","volume":"8","author":"Nitz","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3233\/JND-210735","article-title":"Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen","volume":"9","author":"Rich","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1756286419846058","DOI":"10.1177\/1756286419846058","article-title":"Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment","volume":"12","author":"Wurster","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1111\/jcmm.14939","article-title":"Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients","volume":"24","author":"Faravelli","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/ene.15331","article-title":"Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy","volume":"29","author":"Schorling","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jnc.14953","article-title":"Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy","volume":"153","author":"Kessler","year":"2020","journal-title":"J. Neurochem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1111\/ene.15382","article-title":"Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients","volume":"29","author":"Magen","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_29","unstructured":"Kamali, T., Hagerman, K., Duong, T., Parker, D., Young, S., Tang, W., Sampson, J., and Day, J. (2022). Exploring Protein Changes in Cerebrospinal Fluid of Spinal Muscular Atrophy Patients Pre Nusinersen vs. Post-Nusinersen Treatment using Bayesian Machine Learning Algorithms. Neurology, 98."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ana.25900","article-title":"Clinical Variability in Spinal Muscular Atrophy Type III","volume":"88","author":"Coratti","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Pera, M.C., Coratti, G., Forcina, N., Mazzone, E.S., Scoto, M., Montes, J., Pasternak, A., Mayhew, A., Messina, S., and Sframeli, M. (2017). Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol., 17.","DOI":"10.1186\/s12883-017-0790-9"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mus.26419","article-title":"Revised upper limb module for spinal muscular atrophy: 12 month changes","volume":"59","author":"Pera","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/mus.25120","article-title":"Six-minute walk test is reliable and valid in spinal muscular atrophy","volume":"54","author":"Montes","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","article-title":"Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy","volume":"74","author":"Montes","year":"2010","journal-title":"Neurology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.26633","article-title":"Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy","volume":"60","author":"Montes","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.nmd.2016.10.002","article-title":"Developmental milestones in type I spinal muscular atrophy","volume":"26","author":"Coratti","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","article-title":"Longitudinal natural history of type I spinal muscular atrophy: A critical review","volume":"15","author":"Mercuri","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"McGraw, S., Qian, Y., Henne, J., Jarecki, J., Hobby, K., and Yeh, W.S. (2017). A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol., 17.","DOI":"10.1186\/s12883-017-0853-y"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1241","DOI":"10.1212\/WNL.0000000000008166","article-title":"Long-term progression in type II spinal muscular atrophy: A retrospective observational study","volume":"93","author":"Mercuri","year":"2019","journal-title":"Neurology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.nmd.2020.07.005","article-title":"Age and baseline values predict 12 and 24-month functional changes in type 2 SMA","volume":"30","author":"Coratti","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/acn3.51281","article-title":"Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","volume":"8","author":"Annoussamy","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): A phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nmd.2021.10.009","article-title":"Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes","volume":"32","author":"Coratti","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Montes, J., McDermott, M.P., Mirek, E., Mazzone, E.S., Main, M., Glanzman, A.M., Duong, T., Young, S.D., Salazar, R., and Pasternak, A. (2018). Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199657"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/acn3.51411","article-title":"Nusinersen in pediatric and adult patients with type III spinal muscular atrophy","volume":"8","author":"Pera","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Seo, G., Kim, S., Byun, J.C., Kwon, S., and Lee, Y.J. (Brain Dev., 2023). Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen, Brain Dev., in press.","DOI":"10.1016\/j.braindev.2023.07.005"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","article-title":"NFL is a marker of treatment response in children with SMA treated with nusinersen","volume":"266","author":"Olsson","year":"2019","journal-title":"J. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1111\/jcmm.16802","article-title":"Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen","volume":"25","author":"Johannsen","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Tobacman, J.K., and Bhattacharyya, S. (2022). Profound Impact of Decline in N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on Molecular Pathophysiology and Human Diseases. Int. J. Mol. Sci., 23.","DOI":"10.20944\/preprints202209.0115.v1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s12035-017-0406-9","article-title":"Expression and Distribution of Arylsulfatase B are Closely Associated with Neuron Death in SOD1 G93A Transgenic Mice","volume":"55","author":"Zhang","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/ecco-jcc\/jjx058","article-title":"Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn\u2019s Disease","volume":"11","author":"Feldbrugge","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"14789","DOI":"10.1073\/pnas.1309468110","article-title":"Role of the ectonucleotidase NTPDase2 in taste bud function","volume":"110","author":"Vandenbeuch","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.neuroscience.2005.11.039","article-title":"Nucleoside triphosphate diphosphohydrolase-2 (NTPDase2\/CD39L1) is the dominant ectonucleotidase expressed by rat astrocytes","volume":"138","author":"Wink","year":"2006","journal-title":"Neuroscience"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.molimm.2015.06.008","article-title":"Diverse cellular and organismal functions of the lysosomal thiol reductase GILT","volume":"68","author":"Rausch","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Meneri, M., Abati, E., Gagliardi, D., Faravelli, I., Parente, V., Ratti, A., Verde, F., Ticozzi, N., Comi, G.P., and Ottoboni, L. (2023). Identification of Novel Biomarkers of Spinal Muscular Atrophy and Therapeutic Response by Proteomic and Metabolomic Profiling of Human Biological Fluid Samples. Biomedicines, 11.","DOI":"10.3390\/biomedicines11051254"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Bianchi, L., Sframeli, M., Vantaggiato, L., Vita, G.L., Ciranni, A., Polito, F., Oteri, R., Gitto, E., Di Giuseppe, F., and Angelucci, S. (2021). Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094329"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/acn3.51625","article-title":"Biochemical and clinical biomarkers in adult SMA 3\u20134 patients treated with nusinersen for 22 months","volume":"9","author":"Poesen","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00018-023-04885-7","article-title":"Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: A 2-year follow-up multicenter retrospective study","volume":"80","author":"Faravelli","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13195-022-01113-5","article-title":"Multi-platform proteomic analysis of Alzheimer\u2019s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome","volume":"14","author":"Dammer","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat. Rev. Neurol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/20\/6696\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:10:22Z","timestamp":1760130622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/20\/6696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":63,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["jcm12206696"],"URL":"https:\/\/doi.org\/10.3390\/jcm12206696","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]}}}